Key facts
- AbolerIS Pharma’s last known valuation is $30.0M (Apr 2025).
- It has raised $49.9M; the latest was Accelerator/Incubator ($8.2M) in Apr 2025.
- Notable investors include European Commission, Turenne Groupe, SambrInvest, Société Fédérale de Participations et d'Investissement, Atlanpole — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for AbolerIS Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for AbolerIS Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AbolerIS Pharma
Developer of innovative immunomodulators intended for the treatment of transplant rejection, graft-versus-host disease, and autoimmune diseases. The company's novel and therapeutic approach induces immune tolerance and preserves useful immune responses in inflammatory, autoimmune, and degenerative diseases, enabling researchers to focus on the advancement of novel drugs in areas of unmet medical need.
- Sector
- Healthcare
- HQ
- Gosselies, Belgium
- Founded
- 2019
- Employees
- 13
- Website
- aboleris-pharma.com/
- Ownership
- Privately Held (backing)
AbolerIS Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AbolerIS Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AbolerIS Pharma in its N-PORT filings yet. We sweep new filings monthly.